Advances in medical devices using nanomaterials and nanotechnology: Innovation and regulatory science.

Nanomaterials and nanotechnology are emerging as promising strategies for medical devices due to their advantageous properties, including the ability to effectively interact with biomolecules and tissues, as well as enhance therapeutic efficacy and biocompatibility. This has resulted in approved and candidate devices in fields, such as orthopedics, dentistry, wound care, and neurology. However, the overall progress in translating medical devices using nanomaterials has been relatively slow, highlighting the urgent need to advance regulatory science.

Construction of a Carcinoembryonic Antigen Surface-Enhanced Raman Spectroscopy (SERS) Aptamer Sensor Based on the Silver Nanorod Array Chip.

Carcinoembryonic antigen (CEA) is a cancer-related tumor marker, which is commonly used for preventive screening, auxiliary diagnosis, and recurrence monitoring. Therefore, it is of great significance to develop a new CEA detection method. In this paper, we developed an SERS aptasensor for CEA based on silver nanorod array chip, thiol aptamer, and 4-mercaptophenylboronic acid (4-MPBA).

A novel Apt-SERS platform for the determination of cardiac troponin I based on coral-like silver-modified magnetic substrate and BCA method.

As a kind of acute cardiovascular disease, acute myocardial infarction (AMI) endangers human's life and fitness seriously. The detection of cardiac troponin I (cTnI), a biomarker of AMI, is the key to early medical prognosis and treatment. Surface-enhanced Raman spectroscopy is viewed to be an effective approach for detection of low-concentration substances, and aptamers are regarded to be effective fragments to recognize proteins specifically.

Aptamer-modified magnetic SERS substrate for label-based determination of cardiac troponin I.

A sensitive label-based SERS strategy composed of magnetic bimetallic nanoparticles FeO@Ag@Au, specific aptamer, and Bradford method was developed for the quantitative determination of cardiac troponin I (cTnI) in human serum. The prepared substrate with high magnetic character, signal enhancement, and uniformity exhibited significant Raman response. After the substrate was bound to the aptamer, the target protein cTnI was specifically captured, and it showed the Raman signal when the signal reporter Coomassie Brilliant Blue G-250 (CBBG) was supplied.